高级检索
    徐建明, 刘建化. 肿瘤缓解分级和ERCC1核蛋白表达可以预测胃食管肿瘤患者新辅助化疗的临床效果[J]. 循证医学, 2011, 11(2): 91-93. DOI: 10.3969/j.issn.1671-5144.2011.02.014
    引用本文: 徐建明, 刘建化. 肿瘤缓解分级和ERCC1核蛋白表达可以预测胃食管肿瘤患者新辅助化疗的临床效果[J]. 循证医学, 2011, 11(2): 91-93. DOI: 10.3969/j.issn.1671-5144.2011.02.014
    shu
    XU Jian-ming, LIU Jian-hua. Tumour Regression and ERCC1 Nuclear Protein Expression Predict Clinical Outcome in Patients with Gastro-Oesophageal Cancer Treated with Neoadjuvant Chemotherapy[J]. Journal of Evidence-Based Medicine, 2011, 11(2): 91-93. DOI: 10.3969/j.issn.1671-5144.2011.02.014
    Citation: XU Jian-ming, LIU Jian-hua. Tumour Regression and ERCC1 Nuclear Protein Expression Predict Clinical Outcome in Patients with Gastro-Oesophageal Cancer Treated with Neoadjuvant Chemotherapy[J]. Journal of Evidence-Based Medicine, 2011, 11(2): 91-93. DOI: 10.3969/j.issn.1671-5144.2011.02.014
    shu

    肿瘤缓解分级和ERCC1核蛋白表达可以预测胃食管肿瘤患者新辅助化疗的临床效果

    Tumour Regression and ERCC1 Nuclear Protein Expression Predict Clinical Outcome in Patients with Gastro-Oesophageal Cancer Treated with Neoadjuvant Chemotherapy

      摘要
    • 摘要: 胃食管腺癌的术前新辅助化疗已经成为东西方国家普遍接受的治疗模式。但是,如何预测新辅助化疗的疗效,是所有学者关心的问题。因为,术前有效的患者，预后好: 术前无效的患者,可能因化疗耽误手术的时机,患者的预后就差。所以, 学者们关注的问题仍然是, 谁能从新辅助化疗中获益?

       

      • HTML全文
      • 参考文献(3)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回